Walleye Capital’s ImmunityBio IBRX Stock Holding History

Walleye Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,522	Closed	-$66.5K	–	5540
2024 Q2	$66.5K	Buy	+10,522	New	+$69.4K	﹤0.01%	4860

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's IBRX Position: Q3 2024 in Review

Walleye Capital sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 10,522 shares — an estimated $66.5K sold.

Walleye Capital first reported a position in IBRX in Q2 2024 and held it in 1 quarter. The position peaked at $66.5K in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

Walleye Capital reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 10,522 ImmunityBio shares in Q3 2024, an estimated $66.5K.
Walleye Capital first reported a position in ImmunityBio in Q2 2024 and held it in 1 quarter.
Walleye Capital's ImmunityBio position peaked at $66.5K in Q2 2024.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.